Akèy › Kansè lestomak › Texas › Dallas
Etid klinik pou Kansè lestomak nan Dallas, TX
19 etid pou Kansè lestomak ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- UT Southwestern, Dallas
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Ap rekriteFaz 3
- Baylor Scott & White Health, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- Baylor, Scott and White Research Institute, Dallas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Texas Oncology - DFW (Sammons CC), Dallas
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Ap rekriteFaz 3
- Research Site, Dallas
- Research Site, Dallas
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Ap rekriteFaz 1/2
- Mary Crowley Cancer Research, Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Mary Crowley Cancer Research, Dallas
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Ap rekriteFaz 3
- UT Southwestern Medical Center, Dallas
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Texas Oncology, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- ak 2 plis
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- Texas Oncology - DFW, Dallas
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Ap rekriteFaz 2
- Texas Oncology Dallas Methodist, Dallas
- Texas Oncology Dallas Medical City, Dallas
- Texas Oncology Dallas Presbyterian, Dallas
- ak 2 plis
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Ap rekriteFaz 1/2
- University of Texas Southwestern Medical Center, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Baylor University Medical Center, Dallas
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Dallas, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Dallas
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
Etid Kansè lestomak nan lòt vil
- Houston, TX42 etid
- Boston, MA32 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Baldwin Park, CA22 etid
- Los Angeles, CA22 etid
- Arlington, VA20 etid
- San Antonio, TX19 etid
- St. Louis, MO18 etid
- Grand Rapids, MI18 etid
- Washington, DC16 etid
- Chicago, IL16 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè poumon27 etid
- Kansè vejik27 etid
- Kansè Endomèt24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.